Abstract:BackgroundDuchenne Muscular Dystrophy (DMD) is the most common muscle disease in children, and there are no effective therapies for DMD or Becker Muscular Dystrophy (BMD). Currently, targeted gene therapy treatments have emerged. As a result, genetic diagnosis is the basis of treatment. In addition, genetic and prenatal diagnosis significantly reduces their incidence rates. This study combines the application of multiplex ligation-dependent probe amplification technology (MLPA) and "next-generation" sequencing technology (NGS) as the most economical and efficient method of diagnosis. Therefore, in the diagnosis of DMD/BMD, patients' MLPA data are first used to detect DMD gene deletions or duplications, and NGS and Sanger sequencing are then applied to exclude MLPA-negative samples. Meanwhile, polymerase chain reaction (PCR) is used to detect single exon deletions to exclude false-positives in MLPA caused by point mutations.MethodsIn this study, we recruited 1051 proband families of DMD from 2016 to 2018 and had access to information that could identify individual participants during or after data collection. Patients who were diagnosed with DMD were first tested by MLPA. MLPA results with single exon deletions were validated with PCR amplification and Sanger sequencing. The negative results of MLPA were further analysed with NGS and validated by Sanger sequencing. For novel missense mutations, phenotype-genotype correlations were analysed using PolyPhen2 and mutation taster. All methods were performed in accordance with the relevant guidelines and regulations.ResultsDMD mutations were identified in 1029 families (97.91%, 1029/1051). Large deletions, duplications, and small mutations accounted for 70.41% (740/1051), 8.28% (87/1051), and 19.12% (201/1051) of all cases, respectively. There were 205 small mutation types, 53 of which were novel. The rate of de novo mutations was 39.45% (187/474) and was higher in large duplications (49.53%, 157/317). Among 68 asymptomatic patients (< 3 years old) with unexplained persistent hyperCKaemia upon conventional physical examination, 63 were diagnosed as DMD/BMD according to genetic diagnosis.ConclusionOur results expand the spectrum of DMD mutations, which could contribute to the treatment of DMD/BMD and provide an effective diagnosis method. Thus, the combination of MLPA, NGS and Sanger sequencing is of great significance for family analysis, gene diagnosis and gene therapy.

[Application of Targeted Capture Technology and Next Generation Sequencing in Molecular Diagnosis of Inherited Myopathy].

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

[Diagnosis of mitochondrial disorders in children with next generation sequencing]

Author Response for "genetic Spectrum and Clinical Profiles in a Southeast Chinese Cohort of Charcot‐Marie‐Tooth Disease"

Molecular Diagnostic Approaches to Metabolic Myopathies by Target Gene Capture and Next Generation Sequencing (P07.215)

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

Clinical Diagnosis and Genetic Analysis of Children With Muscular Dystrophies

Mutational spectrum of Chinese LGMD patients by targeted next-generation sequencing

Preliminary application of next-generation Ion Torrent PMGTM platform on genetic diseases in pediatrics

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

Improving molecular diagnosis of Chinese patients with Charcot-Marie-Tooth by targeted next-generation sequencing and functional analysis.

Targeted Next-Generation Sequencing As a Comprehensive Test for Mendelian Diseases: a Cohort Diagnostic Study.

Using Next-Generation Sequencing As A Genetic Diagnostic Tool in Rare Autosomal Recessive Neurologic Mendelian Disorders

The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States

Next generation sequencing panel as an effective approach to genetic testing in patients with a highly variable phenotype of neuromuscular disorders

Exome sequencing in undiagnosed congenital myopathy reveals new genes and refines genes-phenotypes correlations

Application of a Multiplex Ligation-Dependent Probe Amplification-Based Next-Generation Sequencing Approach for the Detection of Pathogenesis of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy Caused by Copy Number Aberrations

Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing

Identification of Gene Mutations in Patients with Primary Periodic Paralysis Using Targeted Next-Generation Sequencing